Search results
Results from the WOW.Com Content Network
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. [ 83 ] Common side effects include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, decreased appetite and swelling of the ...
Cancer treatment needs to be selected to do least harm to both the woman and her embryo/fetus. In some cases a therapeutic abortion may be recommended. Radiation therapy is out of the question, and chemotherapy always poses the risk of miscarriage and congenital malformations. [63] Little is known about the effects of medications on the child.
The platinum-based drugs are the exception; with these drugs, sensation may continue to deteriorate for several months after the end of treatment. [122] Some CIPN appears to be irreversible. [ 122 ] Pain can often be managed with drug or other treatment but the numbness is usually resistant to treatment.
The cancer treatment drug topotecan is a synthetic chemical compound similar in chemical structure to camptothecin which is found in extracts of Camptotheca (happy tree). [7] Catharanthus roseus. Vinca alkaloids were originally manufactured by extracting them from Catharanthus roseus (Madagascar Periwinkle). [1] Podophyllum spp.
It received U.S. Food and Drug Administration (FDA) approval for use in the treatment of advanced prostate cancer patients on April 29, 2010. [16] [17] Interim results from a phase III trial of talimogene laherparepvec in melanoma showed a significant tumour response compared to administration of GM-CSF alone. [7]
Patients and their diseases are profiled in order to identify the most effective treatment for their specific case. Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, [1] others being hormonal therapy and cytotoxic chemotherapy.
The analysis, published in the journal Frontiers in Toxicology, builds upon research published earlier this year, which identified more than 900 chemicals as being potential mammory carcinogens ...
The National Toxicology Program of the U.S. Department of Health and Human Services is mandated to produce a biennial Report on Carcinogens. [37] As of August 2024, the latest edition was the 15th report (2021). [38] It classifies carcinogens into two groups: Known to be a human carcinogen; Reasonably anticipated to be a human carcinogen